Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Targeted CEA CAR-T · 4 trials · 1 indication
Adverse events and their proportion during the trial (assessed against the Common Terminology Standard for Adverse Events Version 5.0 (CTCAE 5.0) and ASTCT standards)
| Arm | Type | Description |
|---|---|---|
| Targeted CEA CAR-T intravenous infusion group | EXPERIMENTAL | - |
| Targeting CEA CAR-T pleural infusion group | EXPERIMENTAL | - |
| Targeted CEA CAR-T intravenous infusion | EXPERIMENTAL | - |
| Targeting CEA CAR-T intraperitoneal infusion group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Targeted CEA CAR-T | BIOLOGICAL | Subjects meeting the transfusion criteria will receive pre-treatment, which is as follows: fludarabine 25mg/m2/d×3day and cyclophosphamide 300mg/m2/d×3day, and intravenous CEA CAR-T therapy after 1-2 days of rest |
Inclusion Criteria: \- Participants must meet all of the following criteria to be eligible for enrollment: 1. Age ≥18 years, regardless of gender. 2. Histologically or cytologically confirmed advanced, metastatic, or recurrent lung cancer, including both non-small cell lung cancer (NSCLC) and sma...
Top 20 of 77 competitors